Me, Myself, and I-healthKathy Kincade, EditorWhen it comes to healthcare, the Internet seems to be suffering from a split personality. Is it a communications backbone or a consumer destination? Like many things in life, it’s a little of
Me, Myself, and I-healthKathy Kincade, Editor
When it comes to healthcare, the Internet seems to be suffering from a split personality. Is it a communications backbone or a consumer destination?
Like many things in life, its a little of both. But if e-health as an industrylet alone a mechanism for improved patient-care deliveryis going to survive, vendors are going to have to do a better job of convincing their customers that the Internet is NOT the World Wide Web, and vice versa.
Why is this important? Because, despite the fact that more and more business transactions are moving onto the Web, healthcare is a very different kind of business. Why consumers are more comfortable revealing their VISA card numbers to an anonymous Webmaster at Amazon.com than their weight or blood pressure to their doctors via a secured site is beyond me, but it likely says more about priorities in American culture than anything else. The problem is, unless you can begin to change consumer perception of the Internet as little more than an online shopping mallan end point rather than a means to an endgetting them to adopt the notion of Internet-based healthcare is going to be a tough sell.
Even so, there is a sense of inevitableness to our migration to the Internet. As a backbone, it just has too many good things to offer, from low-cost data transmission to broad-based interoperability (not to mention all that free stuff). In fact, it was that notionthat the Internet is like some runaway locomotive that will help us in spite of ourselvesthat prompted the stock market/dot-com frenzy we seem to be emerging from these days.
I dont like to see any company go under, but I am not surprised that so many of the e-health companies that took Wall Street by storm last year are struggling. What were they selling, really, except a dream? Superb speculation? A sense of power for those who believed, and impending doom for those who didnt? How many times did you kick yourself for not jumping on the bandwagon as you watched the Dow-Jones soar to record heights earlier this year? (Or maybe that was just me.)
But now the shakeout has begun. Executives are bailing, analysts are downgrading, and shareholders are suing. And as with most things, there is a good side to this and a not-so-good side. Those companies with legitimate business models and products and services will survive, and those who are selling vaporware and snake oil wont. The survivors will mostly be established vendors who have added e-health and ASP components to their businesses, and they likely will be the bigger winnersfor the time being, anyway.
But again, there is an element of inevitability to all of this. Once the dot-coms figure out how to attract both patients and providers to their sites, keep them coming back, and turn a profit in the process, e-healthand all those it toucheswill have found the pot of gold at the end of the Internet rainbow. In the meantime, we can only speculate.
Comments/questions: kkincade@mfi.com
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.